Skip to main content

ams and Precision Biomonitoring announce global partnership to enable pandemic control through the development of a rapid saliva antigen testing device for Covid-19 (SARS-CoV-2)

Today, ams (SIX: AMS), a leading worldwide supplier of high performance sensor solutions, and Precision Biomonitoring, a Canadian-based leader in virus detection tools, announce a global partnership to share technologies to develop an innovative testing device for the Covid-19 (SARS-CoV-2) virus. The partnership will see ams’ innovative spectral sensor technology paired with Precision Biomonitoring’s lateral flow and digital capabilities. The combination is expected to re-imagine mass testing devices for Covid-19 (SARS-CoV-2). Initial results, on inactivated virus particles, indicate a very good sensitivity in the order of cycle time (CT) 31, which could lead to the identification of asymptomatic persons.

“The pandemic is still with us and will continue to be part of our lives well into the new year. This partnership with ams will continue to provide innovative solutions urgently needed by government and authorities to help track and control this virus,” says Dr. Mario Thomas, CEO, Precision Biomonitoring. “We are dedicated to developing quality testing devices and with the addition of this highly-sensitive technology we will continue to change the testing landscape.”

To create innovative solutions and support pandemic control, ams and Precision Biomonitoring are investigating the efficacy and sensitivity of a lab-free lateral-flow test connected to a medical cloud, to detect virus particles in as little as around 15-minutes. The test is focused on detecting the virus at earlier stages of infection, before symptoms have appeared.

The ams spectral sensor solution allows fluorescence-based read out of antigen detection, strengthening ams’ leadership in delivering high-quality professional health diagnostics, designed to improve speed and reliability of rapid, point-of-care diagnostics.

“Governments and authorities need to enable fast, reliable and effective testing. Our initial results for this solution indicate that even asymptomatic patients who carry the virus could be more readily identified. We expect the combination of Precision Biomonitoring and ams technology to become an essential tool in the effort to help control the pandemic and resume the many economic and social activities that comprise what we call normal life,” says Jennifer Zhao, Executive Vice President, division Advanced Optical Sensors, ams. “This is aided by the fact that, once approved, the testing solution can be produced inexpensively and without complex limitations at high scale. We hope that this solution will eliminate complicated logistics and clinical processes and streamline approaches to mass testing.”

For more information about ams spectral sensing, please see


Amy Flécher
ams AG
VP Marketing Communications

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.